Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Hannah Wentzel"'
Autor:
Atefeh Bonyadi, Fariborz Mansour-Ghanaei, Farhang Babamahmoodi, Esmat Radmanesh, Hadiseh Hosamirudsari, Javad Khodadadi, Sara Sayar, Zeinab Mehrabi, Amir Reza Bahadori, Shahin Merat, Minoo Moghimi, Gholamali Eslami, Hashem Mousavi, Lotfollah Davoodi, Mona Ebrahimzadeh, Farahnaz Joukar, Amir Anushiravani, Ali Ali Asgari, Ali Reza Davoudi Badabi, Elham Barahimi, Saeed Jelvay, Zahra Poormontaseri, Aida Zeinali, Nasim Khajavirad, Minoosh Shabani, Hamideh Abbaspour Kasgari, Zohreh Azarkar, Rohollah Moslemi, Ahmad Hormati, Azadeh Ebrahimzadeh, Hani Esmaeilian, Shokrollah Salmanzadeh, Elham Akbarpour, Lili Rezaie Keikhaie, Kaitlyn McCann, Amir Mohammad Shabani, Abdolali Tousi, Mohammad Abdollahi, Sara Mobarak, Mohammadreza Naghipour, Hadi Mirzaei, Mohammadreza Salehi, Shervin Shokouhi, Bryony Simmons, Morteza Mobarak, Helia Nateghi Baygi, Jacob Levi, Mehdi Hassaniazad, Andrew Hill, Zahra Arizavi, Nasrollah Hasooni Bahrini, Seyed Ali Dehghan Manshadi, Fatemeh Dehghani, Hannah Wentzel, Hossein Pourmasoomi, Masoome Noori Jangi, Shoeleh Yaghoubi, Alireza Nateghi Baygi, Mehdi Salasi, Farnaz Zolfaghari, Sara Yeganeh, Elmira Azimi, Jalal Karimi, Hafez Fakheri, Mahdi Afshari, Tofigh Yaghubi Kalurazi, Anahita Sadeghi, Farshid Abedi, Sajedeh Mousaviasl, Zahra Nekoukar, Dorsa Merat, Masood Ziaee
Publikováno v:
Journal of Antimicrobial Chemotherapy
Background: The combination of sofosbuvir (SOF) and daclatasvir (DCV) has shown preliminary efficacy for patients with COVID-19 in five open-label studies with small sample sizes. This larger trial aimed to assess if the addition of sofosbuvir and da
Autor:
Anna Garratt, Jacob Levi, Amir H. Davarpanah, Hannah Wentzel, Zahedin Kheiri, Ali Ali Asgari, Shirin Afhami, Andrew Hill, Amir Anushirvani, Ambar Qavi, Anahita Sadeghi, Hadiseh Hosamirudsai, Rasoul Aliannejad, Bryony Simmons, Shahin Merat, Mahnaz Montazeri, Elham Akbarpour, Alireza Norouzi, Amir Reza Radmard
Publikováno v:
Journal of Antimicrobial Chemotherapy
Background Currently no effective antiviral therapy has been found to treat COVID-19. The aim of this trial was to assess if the addition of sofosbuvir and daclatasvir improved clinical outcomes in patients with moderate or severe COVID-19. Methods T
Autor:
Kaitlyn McCann, Jonathan Falconer, Anna Garratt, Jacob Levi, Hannah Wentzel, Junzheng Wang, Victoria Pilkington, Andrew Hill, Ambar Qavi, Leah Ellis
Publikováno v:
Open Forum Infectious Diseases. 8
Autor:
Jonathan Falconer, Hannah Wentzel, Victoria Pilkington, Andrew Hill, Ambar Qavi, Jacob Levi, Kaitlyn McCann, Anna Garratt, Junzheng Wang, Leah Ellis
Publikováno v:
Open Forum Infectious Diseases. 8
Ivermectin is an antiparasitic drug being investigated for repurposing against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Ivermectin showed in vitro activity against SARS-COV-2, but only at high concentrations. This meta-analysis i
Autor:
Andrew, Hill, Anna, Garratt, Jacob, Levi, Jonathan, Falconer, Leah, Ellis, Kaitlyn, McCann, Victoria, Pilkington, Ambar, Qavi, Junzheng, Wang, Hannah, Wentzel
Publikováno v:
Open Forum Infectious Diseases
Ivermectin is an antiparasitic drug being investigated for repurposing against SARS-CoV-2. Ivermectin showed in-vitro activity against SARS-COV-2 at high concentrations. This meta-analysis investigated ivermectin in 24 randomized clinical trials (332
Autor:
Andrew Hill, Ahmed Abdulamir, Sabeena Ahmed, Asma Asghar, Olufemi Emmanuel Babalola, Rabia Basri, Carlos Chaccour, Aijaz Zeeshan Khan Chachar, Abu Tauib Mohammed Chowdhury, Ahmed Elgazzar, Leah Ellis, Jonathan Falconer, Anna Garratt, Basma Hany, Hashim A Hashim, Wasim Ul Haque, Arshad Hayat, Shuixiang He, Ramin Jamshidian, Wasif Ali Khan, Ravi Kirti, Alejandro Krolewiecki, Carlos Lanusse, Jacob Levi, Reaz Mahmud, Sermand Ahmed Mangat, Kaitlyn McCann, Anant Mohan, Mortezza Shakshi Niaee, Nurullah Okumus, Victoria Pilkington, Chinmay Saha Podder, Ambar Qavi, Houssam Raad, Mohammaed Sadegh Rezai, Surapaneni Sasank, Veerapaneni Spoorthi, Tejas Suri, Junzheng Wang, Hannah Wentzel
Ivermectin is an antiparasitic drug being investigated for repurposing to SARS-CoV-2. In-vitro, ivermectin showed limited antiviral activity and a COVID-19 animal model demonstrated pathological benefits but no effect on viral RNA. This meta-analysis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::efcc6d80423cf6cc9688126d8d0c8e7b
https://doi.org/10.21203/rs.3.rs-148845/v1
https://doi.org/10.21203/rs.3.rs-148845/v1
Autor:
Akbar Hedayatizadeh-Omran, Majid Saeedi, Andrew Hill, Hannah Wentzel, Amir Shamshirian, Reza Alizadeh-Navaei, Jacob Levi, Shahin Merat, Fatemeh Roozbeh
Publikováno v:
Journal of Antimicrobial Chemotherapy
Introduction Effective treatments are urgently needed to tackle the novel coronavirus disease 2019 (COVID-19). This trial aims to evaluate sofosbuvir and daclatasvir versus standard care for outpatients with mild COVID-19 infection. Methods This was
Autor:
Gholamali Eslami, Hamideh Abbaspour Kasgari, Andrew Hill, Shahin Merat, Hannah Wentzel, Ali Ali Asgari, Hafez Fakheri, Anahita Sadeghi, Sara Mobarak, Bryony Simmons
Publikováno v:
Journal of Antimicrobial Chemotherapy
Background The combination of sofosbuvir and daclatasvir has a well-established safety profile and improves clinical outcomes in HCV patients. In silico and in vitro studies suggest that sofosbuvir/daclatasvir may show antiviral activity against SARS
Autor:
Majid Hajizadeh Farsani, Amir Hosein Jafari Kashi, Sara Mobarak, Shokrollah Salmanzadeh, Bryony Simmons, Hani Esmaeilian, Andrew Hill, Zahra Lotfi, Morteza Mobarak, Sajedeh Mousaviasl, Ramin Tabibi, Saeid Bitaraf, Gholamali Eslami, Aseni Wickramatillake, Hannah Wentzel, Anahita Sadeghi, Esmat Radmanesh, Seyed Mehdi Talebzadeh, Sedigheh Marjani, Saeed Jelvay, Mahboobeh Momtazan, James Freeman
Publikováno v:
Journal of Antimicrobial Chemotherapy
Objectives Sofosbuvir and daclatasvir are direct-acting antivirals highly effective against hepatitis C virus. There is some in silico and in vitro evidence that suggests these agents may also be effective against SARS-CoV-2. This trial evaluated the
Autor:
Hannah Wentzel, Junzheng Wang, Abbienaya Dayanamby, Victoria Pilkington, Jacob Levi, Andrew Hill, Leah Ellis
Publikováno v:
Open Forum Infectious Diseases
Background There is a continued and pressing need for safe and effective treatment of COVID-19. Significant survival benefits have been shown by dexamethasone, tocilizumab and sarilumab, however they are only recommended in hospitalised COVID-19 pati